Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

28.55 -0.61 (-2.09%)
Streaming Delayed Price Updated: 12:14 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential ↗
GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors ↗
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors ↗
GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. ↗
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock 
Via Chartmill
News headline image
Breaking Down Genmab: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
Via Chartmill
News headline image
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗
NASDAQ:GMAB is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?. ↗
Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB) ↗
Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR... 
Via Chartmill
News headline image
Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability. ↗
GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
News headline image
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish ↗
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize... 
Via Stocktwits
Topics Stocks
News headline image
What Analysts Are Saying About Genmab Stock ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗
NASDAQ:GMAB, a growth stock which is not overvalued. 
Via Chartmill
News headline image
A Closer Look at 10 Analyst Recommendations For Genmab ↗
 
Via Benzinga
News headline image
Preview: Genmab's Earnings ↗
 
Via Benzinga
News headline image
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy? ↗
Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy? 
Via Chartmill
News headline image
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer ↗
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. 
Via Benzinga
News headline image
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio? 
Via Benzinga
News headline image
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—a stock with solid growth prospects and a reasonable valuation. ↗
GENMAB A/S -SP ADR was identified as an affordable growth stock. NASDAQ:GMAB is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
News headline image
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
In a market where value is scarce, NASDAQ:GMAB offers a refreshing opportunity with its solid fundamentals. ↗
Take a closer look at GENMAB A/S -SP ADR , a remarkable value stock. NASDAQ:GMAB excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗
Uncover the potential of GENMAB A/S -SP ADR, a growth stock reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Based on technical and fundamental analysis of NASDAQ:GMAB we find: GENMAB A/S -SP ADR (NASDAQ:GMAB) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB. ↗
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.